COMPOUNDS USEFUL IN COATING STENTS TO PREVENT AND TREAT STENOSIS AND RESTENOSIS

摘要

At least one bioactive agent is locally delivered to a location where a stent is implanted within a lumen in a patient's body. The bioactive agent includes a: DNA minor groove binder (such as CC-1065 or Duocarmycin); apocynin; RGD peptide (such as RGDfV); stilbene compound (such as resveratrol); camptothecin; des-aspartate angiotensin I; or ADF; or an analog or derivative thereof; or a combination or blend thereof with at least one other bioactive agent. The bioactive agent is generally locally delivered, such as by elution from the stent. The compounds and methods are of particular benefit for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, occlusive disease, or other abnormal lumenal cellular proliferation condition.